BCL3: A Protein Target for Drug and Biomarker Development (G602)

Target Name: BCL3

NCBI ID: G602

BCL3

BCL3: A Protein Target for Drug and Biomarker Development

BCL3 (Bcl-3 protein) is a protein that is expressed in a variety of tissues throughout the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a member of the Bcl family of proteins, which are known for their ability to regulate cell death and cell survival.

The BCL3 protein is involved in a variety of physiological processes in the body, including cell signaling, DNA replication, and stress response. It has also been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of BCL3 is its potential as a drug target. BCL3 has been shown to be involved in a variety of cellular processes that are associated with the development and progression of disease, including cell signaling, angiogenesis, and inflammation. As such, it is a potential target for a variety of therapeutic approaches, including small molecule inhibitors, monoclonal antibodies, and adoptive T cell therapy.

In addition to its potential as a drug target, BCL3 is also a potential biomarker for a variety of diseases. Its expression has been shown to be associated with the development of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, BCL3 has the potential to be used as a biomarker for these diseases, and may be useful for the diagnosis and prognosis of these conditions.

The discovery and characterization of BCL3 as a potential drug target and biomarker is an exciting area of research, with implications for the treatment of a wide range of diseases. Further studies are needed to fully understand the role of BCL3 in disease and to develop effective therapies for the treatment of BCL3-related conditions.

Protein Name: BCL3 Transcription Coactivator

Functions: Contributes to the regulation of transcriptional activation of NF-kappa-B target genes. In the cytoplasm, inhibits the nuclear translocation of the NF-kappa-B p50 subunit. In the nucleus, acts as transcriptional activator that promotes transcription of NF-kappa-B target genes. Contributes to the regulation of cell proliferation (By similarity)

The "BCL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets